Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

A Novel Global Medicines Agency (GMA) Formation Proposal for Making Biotechnology Drugs Affordable: Starting with the League of Arab States.

Version 1 : Received: 5 June 2023 / Approved: 6 June 2023 / Online: 6 June 2023 (08:49:00 CEST)

A peer-reviewed article of this Preprint also exists.

Niazi, S.K. A Proposed Global Medicines Agency (GMA) to Make Biological Drugs Accessible: Starting with the League of Arab States. Healthcare 2023, 11, 2075. Niazi, S.K. A Proposed Global Medicines Agency (GMA) to Make Biological Drugs Accessible: Starting with the League of Arab States. Healthcare 2023, 11, 2075.

Abstract

Additionally, the League’s four observing states, with an additional population of 1.7 billion, if join the group, will form the world’s largest consortium to enhance the accessibility of biotechnology drugs. This effort will also remove the criticism of regulatory agencies that are well-equipped to regulate these products. This should also be a significant economic incentive to consortium states to develop these products, particularly biosimilars, to capture the most critical market anticipated. This plan will also reduce the cost burden on regulatory agencies. The program is divided into two classifications; for products sold in any of the Stringent Regulatory Authority (SRA) states, the registration is automatic but with several requirements that assure ongoing pharmacovigilance; this also applies to copies of reference products or biosimilars. For non-SRA sourcing, a stepwise plan requiring a rapporteur review, as practiced by the EMA and a third-party cGMP audit, is necessary to ensure data and product integrity. However, to reduce the cost burden, approval of these products is based on current scientific findings as presented in this paper.

Keywords

Biosimilars 1; Arab states 1; regulatory guideline 3; harmonization 4; centralized approval 5; EMA 6; FDA 7; Global Medicine Authority (GMA) 8.

Subject

Public Health and Healthcare, Health Policy and Services

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.